<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106611</url>
  </required_header>
  <id_info>
    <org_study_id>14-017</org_study_id>
    <nct_id>NCT02106611</nct_id>
  </id_info>
  <brief_title>Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors</brief_title>
  <official_title>Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      This study will test whether cardiac MRI can improve early detection of Hodgkin lymphoma&#xD;
      associated heart disease compared to a stress echocardiogram. By doing both stress&#xD;
      echocardiography and cardiac MRI, we will compare the ability of the two tests to detect&#xD;
      heart disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>compare the prevalence of cardiac injury</measure>
    <time_frame>2 years</time_frame>
    <description>detected by cardiac MRI to that detected by stress echocardiography among a broadly representative cohort of Hodgkin lymphoma survivors.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">133</enrollment>
  <condition>Hodgkin Lymphoma Survivor</condition>
  <arm_group>
    <arm_group_label>Hodgkin Lymphoma Survivor</arm_group_label>
    <description>This is a prospective cross-sectional study of 200 HL survivors whose treatment included mediastinal RT at initial diagnosis or relapse, and are at least 5 years from last HL treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Assessment</intervention_name>
    <description>HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.</description>
    <arm_group_label>Hodgkin Lymphoma Survivor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stress cardiac MRI</intervention_name>
    <description>Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.</description>
    <arm_group_label>Hodgkin Lymphoma Survivor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stress echocardiogram</intervention_name>
    <description>Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.</description>
    <arm_group_label>Hodgkin Lymphoma Survivor</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        MSKCC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Classical or nodular lymphocyte predominant HL treated at Memorial Sloan-Kettering&#xD;
             Cancer Center.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Treatment for HL that included mediastinal RT at initial diagnosis or relapse.&#xD;
&#xD;
          -  ≥ 5 years from last HL treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary HL diagnosis prior to 1980.&#xD;
&#xD;
          -  Additional mediastinal RT or subsequent cardiotoxic systemic therapy for secondary&#xD;
             malignant neoplasm.&#xD;
&#xD;
          -  Known CAD/CHF (defined as documented myocardial infarction, cardiac revascularization,&#xD;
             angiographic obstructive CAD, or decreased LV function [EF &lt; 55%] during prior&#xD;
             clinical care).&#xD;
&#xD;
          -  Contraindication to MRI (i.e. pacemakers, defibrillators, or aneurysm clips, or other&#xD;
             implanted ferromagnetic objects), gadolinium (i.e. known hypersensitivity to&#xD;
             gadolinium, advanced renal insufficiency as defined by glomerular filtration rate &lt;30&#xD;
             ml/min/1.73m^2).&#xD;
&#xD;
          -  Contraindication to exercise stress testing other than the above (i.e. unstable angina&#xD;
             or severe valvular stenosis).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Matasar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>stress echo</keyword>
  <keyword>Clinical Assessment</keyword>
  <keyword>14-017</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

